Discover more near‑term opportunities with better event intelligence.
Fundz combines its own real-time funding and M&A intelligence with executive moves, hiring shifts and other company changes, weighs each signal against your ideal customer profile, and delivers a ranked daily shortlist with the context and decision maker to contact. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Cytotrait raised £3M in seed funding to expand its MOSS platform for crop trait development and genome editing.
PRIVATESep 29, 2026
Amount Raised
£3 Million
Round Type
Seed
BiotechnologyAgriculture and Farming
Description
Cytotrait, a biotechnology company focused on organelle editing for crop trait development, closed a £3M seed round in 2026. The funding will support expansion of the company's proprietary Mutant Organelle Selection System (MOSS) platform and establish trait enhancement programmes in major crop species. The company also announced the appointment of Dr Ian Jepson, a genome editing expert with 35+ years at Syngenta, as Non-Executive Director to guide strategy and commercialisation efforts.
Company Information
Company
Cytotrait
About
Cytotrait is a biotechnology company based in Manchester, UK, focused on developing novel traits for food and agriculture. Their proprietary technology, the Mutant Organelle Selection System (MOSS), enables the introduction of genes and gene edits into organelles to generate homoplasmy. This approach allows the engineering of traits with high-level expression and promises increased yield, pest resistance, and improved crop development. The company aims to leverage its technology for substantial commercial opportunities in the agricultural sector.
Fundz sees it the moment Cytotrait raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
